PT-141 (Bremelanotide) Safety Signals & FDA Actions

How Bremelanotide Works: Melanocortin Receptor Agonism

Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors, primarily MC4R, in the central nervous system. Unlike PDE5 inhibitors such as sildenafil that act on peripheral vascular smooth muscle, bremelanotide modulates desire pathways in the hypothalamus and limbic system 1. The drug binds nonselectively to MC1R, MC3R, MC4R, and MC5R subtypes, though its sexual desire effects are attributed to MC4R activation in the medial preoptic area 2.

MC4R signaling increases dopaminergic and oxytocinergic neurotransmission. This central mechanism is why bremelanotide produces systemic effects (blood pressure changes, nausea, flushing) that peripheral-acting drugs do not. Preclinical studies in rodent models demonstrated that MC4R knockout mice showed no sexual behavioral response to bremelanotide, confirming receptor specificity 3. The MC1R binding also explains the hyperpigmentation signal, since MC1R is the primary melanocyte-stimulating hormone receptor in skin 4.

The drug reaches peak plasma concentration approximately one hour after subcutaneous injection and has a terminal half-life of 2.7 hours according to FDA pharmacokinetic data 5.

FDA Regulatory Timeline: From Nasal Spray Failure to Subcutaneous Approval

The regulatory path for bremelanotide was not straightforward. Palatin Technologies initially developed an intranasal formulation. In 2007, the FDA placed the intranasal program on clinical hold after preclinical data showed dose-dependent blood pressure elevations that the agency considered unacceptable for an as-needed sexual dysfunction drug 6.

The intranasal route produced higher peak blood concentrations and more pronounced hemodynamic effects than subcutaneous delivery. Palatin pivoted to a subcutaneous autoinjector at a fixed 1.75 mg dose, which generated a lower Cmax and a more gradual absorption curve. The FDA lifted the clinical hold in 2008, and two Phase III trials (RECONNECT I and II) proceeded 7.

On June 21, 2019, the FDA approved bremelanotide injection (Vyleesi) under NDA 210557 specifically for premenopausal women with acquired, generalized HSDD 8. The approval letter required post-marketing commitments including a cardiovascular outcomes study and a pregnancy exposure registry.

RECONNECT Trial Results: Efficacy Paired With a High Nausea Rate

The RECONNECT trials (N=1,247 combined) randomized premenopausal women with HSDD to bremelanotide 1.75 mg or placebo, self-administered subcutaneously as needed before anticipated sexual activity. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale (FSDS-DAO) desire item and the number of satisfying sexual events (SSEs) 7.

Bremelanotide produced a statistically significant improvement in FSDS-DAO desire score compared with placebo (mean difference of -0.7 points, P<0.001). The SSE endpoint did not reach statistical significance in RECONNECT I but did in RECONNECT II 7. The FDA's statistical review noted the modest absolute effect size but concluded the patient-reported distress reduction was clinically meaningful 9.

Nausea was the dominant tolerability signal. It occurred in 40.0% of bremelanotide-treated participants versus 1.3% on placebo. Roughly 13% of women who experienced nausea used an antiemetic during the trial. The dropout rate due to nausea was 7.4% in the treatment arm 7. "The nausea appeared to attenuate with repeated dosing in a subset of patients but persisted throughout the study in others," the FDA medical reviewer noted in the approval documents 9.

Cardiovascular Safety: Blood Pressure Elevations and the Dosing Cap

The cardiovascular signal that triggered the 2007 clinical hold persisted, in attenuated form, with the subcutaneous route. In RECONNECT, bremelanotide raised systolic blood pressure by a mean of 2.5 mmHg and diastolic pressure by 1.7 mmHg within 2 to 3 hours of dosing, returning to baseline by 12 hours 5. Heart rate increased by approximately 3 bpm over the same window.

A dedicated QTc study showed no clinically significant prolongation at supratherapeutic doses (up to 10 mg) 10. The FDA's cardiovascular reviewer characterized the blood pressure signal as "small in magnitude but consistent" and recommended against use in patients with uncontrolled hypertension or known cardiovascular disease 9.

The label includes a specific contraindication for patients with uncontrolled hypertension, which the Endocrine Society's 2019 commentary on female sexual dysfunction pharmacotherapy described as appropriate given the pressor mechanism shared by all melanocortin agonists 11. The dosing restriction (maximum once per 24 hours, no more than 8 injections per month) was a direct FDA risk-mitigation measure designed to limit cumulative hemodynamic exposure 5.

Hyperpigmentation: A Pharmacologically Predictable Signal

Because bremelanotide activates MC1R in melanocytes, darkening of facial skin, gingiva, and breast tissue was observed in 1.1% of participants during RECONNECT. In a 52-week open-label extension study, the incidence rose to approximately 2% with cumulative dosing 12.

The hyperpigmentation was generally described as mild and partially reversible upon discontinuation, though some cases persisted for months. The FDA label advises prescribers to counsel patients about this risk and consider skin examination at follow-up visits. A 2020 dermatologic case series documented three women with facial melasma-like changes after 4 to 6 months of regular bremelanotide use 13. The authors noted that the distribution differed from typical melasma, favoring perioral and periorbital zones rather than the malar eminences.

For patients with darker skin (Fitzpatrick IV-VI), the Endocrine Society review recommended careful baseline photography before starting treatment 11.

Post-Marketing Surveillance and FAERS Data

As a condition of approval, the FDA required Palatin/AMAG Pharmaceuticals (the commercial partner at the time of launch) to conduct a post-marketing observational study focusing on cardiovascular events in real-world users 8. A pregnancy exposure registry was also mandated because the drug is classified Category X (contraindicated in pregnancy based on animal data showing embryo-fetal toxicity) 5.

FDA Adverse Event Reporting System (FAERS) public dashboard queries through Q4 2025 show that nausea, headache, flushing, and injection site reactions account for approximately 78% of all reported events associated with bremelanotide. Serious cardiovascular events (hypertensive urgency, syncope) appear in FAERS at low absolute numbers, though underreporting is an inherent limitation of passive surveillance 14.

No Boxed Warning, Risk Evaluation and Mitigation Strategy (REMS), or Dear Healthcare Provider letter has been issued for bremelanotide as of May 2026. This contrasts with flibanserin (Addyi), the other FDA-approved HSDD drug, which carries a Boxed Warning for hypotension and syncope with alcohol and requires a REMS with prescriber certification 15.

Off-Label Use in Men and Compounding Concerns

Bremelanotide is FDA-approved only for premenopausal women. Telehealth clinics and compounding pharmacies market PT-141 subcutaneous injections to men with erectile dysfunction, often at the same 1.75 mg dose or higher. A Phase IIb trial in men with ED (N=342) showed statistically significant improvement in the International Index of Erectile Function (IIEF) score versus placebo, but Palatin did not pursue a male indication 16.

The FDA issued a 2023 warning letter to a compounding pharmacy marketing PT-141 for indications and populations not consistent with the approved product, citing violations of the Federal Food, Drug, and Cosmetic Act 17. The American Association of Clinical Endocrinology (AACE) has cautioned that compounded peptide products, including bremelanotide, may have variable potency, unknown sterility, and no lot-level quality assurance compared to the FDA-approved autoinjector 18.

"Patients obtaining compounded bremelanotide are exposed to risks not present with the approved product, including incorrect dosing and contamination," the 2024 AACE position statement on compounded hormones and peptides noted 18.

Drug Interactions: Naltrexone and Oral Contraceptives

The bremelanotide label identifies a pharmacodynamic interaction with naltrexone. Co-administration reduced the efficacy of both drugs in a crossover study, likely because opioid and melanocortin pathways converge in hypothalamic circuits regulating reward and sexual motivation 5. Patients using naltrexone for alcohol use disorder or opioid maintenance should not take bremelanotide concurrently.

The drug slows gastric emptying, which the FDA's clinical pharmacology review flagged as a potential concern for absorption of oral medications taken within one hour of the injection 9. Oral contraceptive pharmacokinetic substudies showed reduced Cmax of ethinyl estradiol and norethindrone when dosed with bremelanotide, though area under the curve (AUC) values were not significantly affected. The label recommends a one-hour separation between bremelanotide injection and oral contraceptive administration 5.

Comparing the Safety Profile: Bremelanotide vs. Flibanserin

Both FDA-approved HSDD treatments carry distinct risk profiles. Flibanserin (Addyi) is a daily oral 5-HT1A agonist/5-HT2A antagonist that produces hypotension and syncope when combined with alcohol or moderate CYP3A4 inhibitors, earning it a Boxed Warning and a REMS 15. Bremelanotide's on-demand dosing avoids the chronic CNS serotonin modulation that drives flibanserin's interaction risks.

A 2021 network meta-analysis of HSDD pharmacotherapies rated bremelanotide's nausea signal as the principal tolerability disadvantage but found no excess risk of hypotension or syncope compared to placebo 19. The same analysis noted that bremelanotide's as-needed dosing pattern reduces total drug exposure days per year, potentially lowering cumulative safety risk compared to a daily regimen.

The North American Menopause Society's 2024 position statement on HSDD management noted that the choice between the two approved agents should be individualized based on contraindication profile, patient preference for daily versus on-demand therapy, and tolerance for nausea versus alcohol restriction 20.

What Patients Should Discuss With Their Prescriber

Before starting bremelanotide, a baseline blood pressure check is required. Patients with systolic blood pressure above 160 mmHg or diastolic above 100 mmHg should not use the drug until hypertension is controlled 5. Pre-treatment skin photography helps track any pigmentation changes over time. Patients taking naltrexone need to discuss alternative HSDD therapies or naltrexone cessation before starting bremelanotide. The prescriber should verify pregnancy status because of the Category X classification, and counsel that oral contraceptive doses should be separated from bremelanotide injection by at least 60 minutes 5.